Loading…
Morepen Laboratories (MOREPENLAB)₹99.15+5.00%Pharmaceuticals
Morepen Laboratories is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 29.2 against a peer median of 34.6, and ROCE of 8.0% against a peer median of 12.1%, and latest-quarter sales growth of 80.9% against a peer median of 20.8%. By market cap it is #4 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FDC | 6,425 | 20.6 | 15.0 | 11.3 | 0.01 | 1.3 | 2,173 | 282 | 20.8 | 74.8 | vs MOREPENLAB |
| Innova Captab | 6,118 | 39.9 | 15.0 | 13.7 | 0.32 | 0.2 | 1,627 | 141 | 33.8 | 42.0 | vs MOREPENLAB |
| IOL Chemicals and Pharmaceuticals | 5,967 | 29.4 | 11.1 | 8.4 | 0.08 | 0.5 | 2,312 | 138 | 40.1 | 116.5 | vs MOREPENLAB |
| Morepen Laboratories | 5,433 | 29.2 | 8.0 | 5.3 | 0.17 | 0.2 | 1,808 | 96 | 80.9 | 117.0 | — |
| Senores Pharmaceuticals | 5,417 | 40.6 | 15.0 | 13.5 | 0.37 | 0.0 | 632 | 122 | 18.6 | 23.4 | vs MOREPENLAB |
| Orchid Pharma | 5,291 | 421.0 | 2.0 | 1.3 | 0.28 | 0.0 | 1,229 | 10 | 15.5 | — | vs MOREPENLAB |
| Supriya Lifescience | 5,082 | 24.3 | 25.1 | 19.1 | 0.00 | 0.2 | 826 | 209 | 50.7 | 48.1 | vs MOREPENLAB |
| SMS Pharmaceuticals | 4,809 | 46.8 | 13.0 | 14.2 | 0.46 | 0.1 | 886 | 102 | 5.6 | 4.9 | vs MOREPENLAB |
| Gufic Biosciences | 4,760 | 64.8 | 12.0 | 10.2 | 0.61 | 0.0 | 948 | 64 | 16.6 | 69.1 | vs MOREPENLAB |
| Aarti Drugs | 4,563 | 24.0 | 12.1 | 13.4 | 0.37 | 0.4 | 2,564 | 194 | 18.9 | −7.5 | vs MOREPENLAB |
| Zota Health Care | 4,410 | — | −8.0 | −15.1 | 0.39 | 0.1 | 539 | −74 | 54.2 | — | vs MOREPENLAB |
| Peer median | 5,291 | 34.6 | 12.1 | 11.3 | 0.32 | 0.2 | 1,229 | 122 | 20.8 | 48.1 |
Listed companies closest to Morepen Laboratories in Pharmaceuticals include FDC, Innova Captab, IOL Chemicals and Pharmaceuticals, Senores Pharmaceuticals, Orchid Pharma, Supriya Lifescience, SMS Pharmaceuticals, Gufic Biosciences.
FDC, with a market cap of ₹6,425 Cr.
Morepen Laboratories trades at a P/E of 29.2; the median of its peer set is 34.6. A P/E above or below the median is a description, not a judgement on value.
Morepen Laboratories' return on capital employed is 8.0%, below the peer median of 12.1%.